Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986489 · 3 trials · 3 indications
Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause.
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| BMS-986489 (atigotatug + nivolumab) | EXPERIMENTAL | Participants will receive a fixed dose of BMS-986489 (atigotatug + nivolumab) intravenously each cycle. Cycles will be 28 days. Up to 125 participants will be enrolled into this arm. |
| Durvalumab | ACTIVE_COMPARATOR | Participants will receive standard of care Durvalumab intravenously each cycle. Cycles will be 28 days. Up to 125 participants will be enrolled into this arm. |
| BMS-986489 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986489 (Atigotatug+Nivolumab) | BIOLOGICAL | Specified dose on specified days |
| Atezolizumab | BIOLOGICAL | Specified dose on specified days |
| Carboplatin | DRUG | Specified dose on specified days |
| Etoposide | DRUG | Specified dose on specified days |
| BMS-986489 | DRUG | BMS-986489 (fixed dose combination of atigotatug + nivolumab) will be administered as an intravenous infusion to be given once every 4 weeks for up to 2 years. |
| Durvalumab | DRUG | Durvalumab will be administered as a fixed dose intravenous infusion to be given once every 4 weeks for up to 2 years. |
Inclusion Criteria * Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). * Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale. * Participants must have at least one tumor that can be measured...
BMS-986489 is being developed for the treatment of small cell lung cancer, including extensive-stage small cell lung cancer, limited-stage small cell lung cancer, and small cell lung carcinoma. It is an investigational monoclonal antibody combination therapy and is not yet approved for any indication.
BMS-986489 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is running clinical trials of the agent in small cell lung cancer across multiple countries.
BMS-986489 is in Phase 3 clinical development. The Phase 3 TIGOS trial is currently recruiting participants with extensive-stage small cell lung cancer, while a Phase 2 trial in limited-stage disease is active but not recruiting.
BMS-986489 has been studied in three registered trials. NCT06646276 is a recruiting Phase 3 trial in extensive-stage small cell lung cancer. NCT06773910 is an active Phase 2 trial in limited-stage disease. NCT06799286 is a completed Phase 1 trial in Chinese participants with relapsed or refractory small cell lung cancer.